NEW YORK (GenomeWeb News) – Cancer diagnostics startup On-Q-ity said today that it has closed a $21 million Series A financing round to support the development of a biomarker-based diagnostic for predicting and monitoring cancer treatment effectiveness.

MDV-Mohr Davidow Ventures led the financing round, which also included Bessemer Venture Partners, Physic Ventures, and Northgate Capital.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.